Navigation Links
Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
Date:12/2/2013

etes – Nancy knows very well that many patients around the world still need new treatment alternatives that can provide even better medical control, as well as markedly better compliance rates with their medicines over time. "I am very interested in new medicines that have the potential to be game changers in the treatment of serious diseases, and I see opportunities at Intarcia not only with ITCA 650 but in the Company's longer-term pipeline initiatives.  I look forward to working with the Board and senior leadership to help to advance these programs and create the type of clinical outcomes success that will benefit patients."

About ITCA 650
ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
3. Scientists develop way to successfully give nanoparticle therapeutics orally
4. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
5. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
8. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
11. Convoy Therapeutics Appoints Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The new , Healthcare ... , available today on PharmaBoardroom.com for free ... that rocked the Spanish economy in 2009, and the austerity ... has remained pragmatic in times of trouble. "Despite ... fifth biggest European market, and the general conditions to invest ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: ... early-stage algae bioactive compounds and metabolic processes, is pleased to ... board of directors. Ms. Nola E. Masterson , a ... joined the board effective September 17, 2014. ... to join our board," states Andrew Dahl , President ...
(Date:9/18/2014)... 18, 2014 On Tuesday, Secretary of ... Jim Risch for National Lab Day on the Hill. ... the national laboratory system. Durbin and Risch also formally ... increase awareness of the reach of the national labs ... to address some of our nation's most pressing challenges. ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3POCT Market in China 2014-2018 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... Sept. 5 CryoLife, Inc. (NYSE: CRY ... announced,today that D. Ashley Lee, executive vice president, ... Inc., is scheduled to present at,the Bear Stearns ... at 4:30 p.m. EDT. Mr. Lee will also ...
... Medarex, Inc.,(Nasdaq: MEDX ) today announced ... its licensing partner, Centocor R&D, Inc. The,extended relationship ... Antibody Development System(R) for the generation of fully,human ... Under the terms of the new agreement, Centocor ...
... Very Robust Findings on the Key Problems Faced by ... Host a Conference Call Today at 11:00 am CET ... Directly From the Worldsleep07 Congress in,Australia HAMBURG, Germany ... Exchange: EVT),presented today at the worldsleep07 congress in Cairns, ...
Cached Biology Technology:Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 2Medarex Announces Extension of Broad Antibody Development Relationship with Centocor 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 2Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 4
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening ... a few short months, earning it the first-ever Newborn Screening ... March of Dimes presented Will Humble, M.P.H., Arizona,s Department of ... here today. Mr. Humble established a policy of full transparency ... send newborn blood samples to the lab for analysis, and ...
(Date:9/18/2014)... seem to be cheerful, happy-go-lucky characters, so you might ... life. , In fact some dogs are distinctly ... Sydney shows. , "This research is exciting because ... objectively and non-invasively. It offers researchers and dog owners ... that changes," said Dr Melissa Starling, from the Faculty ...
(Date:9/18/2014)... devastated algal forests in the eastern Mediterranean Sea pose ... their distribution continues to expand as the climate warms, ... team of researchers led by Dr Adriana Vergs of ... Institute for Advanced Studies in Spain, is published in ... team surveyed more than 1000 kilometres of coastline in ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Dogs can be pessimists too 2Dogs can be pessimists too 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... Santa Barbara have developed new methods for studying how environmental ... spatial and temporal scales. The scientists merged data collected ... canopies taken by the Landsat 5 Thematic Mapper. The findings ... issue of Marine Ecology Progress Series. In ...
... of State Foresters released the first phase of the Southern ... areas forest managers will focus on to maintain southern forests ... urbanization, bioenergy use, weather patterns, land ownership changes and invasive ... 2010 and 2060. About 23 million acres of forest ...
... is available in Spanish . The ... Ikerbasque, is participating in the AWIN -Animal Welfare Indicators project. ... international experts in animal welfare from 11 centres. The group ... University of Edinburgh on the 10 and 11 of May, ...
Cached Biology News:UCSB scientists track environmental influences on giant kelp with help from satellite data 2UCSB scientists track environmental influences on giant kelp with help from satellite data 3Forest Service unveils first comprehensive forecast on southern forests 2Forest Service unveils first comprehensive forecast on southern forests 3Neiker-Tecnalia participates in a European project for improving the welfare of farm animals 2Neiker-Tecnalia participates in a European project for improving the welfare of farm animals 3
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
PA coated Agarose beads LPA Beads...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Biology Products: